Hit and lead identification: Integrated technology-based approaches

Drug Discovery Today: Technologies

Volumn 3, Issue 4, 2006, Pages 367-375

  Goodnow Jr , Robert A ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; ATORVASTATIN; COMPACTIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; DRUG; ENFUVIRTIDE; MELANOCORTIN 4 RECEPTOR; MEVINOLIN; NATURAL PRODUCT; PEPTIDE DERIVATIVE; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN KINASE INHIBITOR;

AUTOMATION; BIOCHEMISTRY; CELL ASSAY; COMBINATORIAL LIBRARY; COMPUTER MODEL; DRUG DESIGN; DRUG IDENTIFICATION; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; MALE SEXUAL DYSFUNCTION; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATENT; PROCESS OPTIMIZATION; PROCESS TECHNOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 33846502057     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2006.12.009     Document Type: Review

References (46)

1. Schuffenhauer A., et al. Molecular diversity management strategies for building and enhancement of diverse and focused lead discovery compound screening collections. Comb. Chem. High Throughput Screen. 7 (2004) 771-781
2. Jacoby E., et al. Key aspects of the Novartis Compound Collection Enhancement Project for the compilation of a comprehensive chemogenomics drug discovery screening collection. Curr. Top. Med. Chem. 5 (2005) 397-411
3. Moy F.J., et al. MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy. Anal. Chem. 73 (2001) 571-581
4. Karlsson R., et al. Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors. Anal. Biochem. 278 (2000) 1-13
5. Bowen W.P., and Wylie P.G. Application of laser-scanning fluorescence microplate cytometry in high content screening. Assay Drug Dev. Tech. 4 (2006) 209-221
6. Pipalia N.H., et al. Automated microscopy screening for compounds that partially revert cholesterol accumulation in Niemann-Pick C cells. J. Lipid Res. 47 (2006) 284-301
7. Miller J.L. Recent developments in focused library design: targeting gene-families. Curr. Top. Med. Chem. 6 (2006) 19-29
8. Ford M.G., et al. Selecting compounds for focused screening using linear discriminant analysis and artificial neural networks. J. Mol. Graphics Model. 22 (2004) 467-472
9. Cano M., and Balasubramanian S. From the combinatorial chemistry boom to polymer-supported parallel chemistry: established technologies for drug discovery. Drugs Fut. 28 (2003) 659-678
10. Golebiowski A., et al. Lead compounds discovered from libraries: Part 2. Curr. Opin. Chem. Biol. 7 (2003) 308-325
11. Van Dongen M.J.P., et al. Structure-based screening as applied to human fabp4: a highly efficient alternative to hts for hit generation. J. Am. Chem. Soc. 124 (2002) 11874-11880
12. Chen C., et al. Convergent diversity-oriented synthesis of small-molecule hybrids. Angew. Chem., Int. Ed. 44 (2005) 2249-2252
13. Tan D.S. Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat. Chem. Biol. 1 (2005) 74-84
14. Kuruvilla F.G., et al. Dissecting glucose signaling with diversity-oriented synthesis and small-molecule microarrays. Nature 416 (2002) 653-657
15. Haggarty S.J., et al. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol. 10 (2003) 383-396
16. Newman D.J., et al. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66 (2003) 1022-1037
17. Piggott A.M., and Karuso P. Quality, not quantity: The role of natural products and chemical proteomics in modern drug discovery. Comb. Chem. High Throughput Screen. 7 (2004) 607-630
18. Haustedt L.O., et al. Rational approaches to natural-product-based drug design. Curr. Opin. Drug Discov. Dev. 9 (2006) 445-462
19. Endo A. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. J. Med. Chem. 28 (1985) 401-405
20. Alberts A.W., et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethyl-glutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. U S A 77 (1980) 3957-3961
21. Congreve M., et al. Structural biology and drug discovery. Drug Discov. Today 13 (2005) 895-907
22. Willians S.P. Recent applications of protein crystallography and structure-guided drug design. Curr. Opin. Chem. Biol. 9 (2005) 371-380
23. McInnes C., et al. Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors. Chem. Biol. 11 (2004) 525-534
24. Combs A.P., et al. Structure-based design and discovery of protein tyrosine phosphastase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics. J. Med. Chem. 48 (2005) 6544-6548
25. Ripka A.S., and Rich D.H. Peptidomimetic design. Curr. Opin. Chem. Biol. 2 (1998) 441-452
26. LaBonte J., et al. Fresh from the pipeline: Enfuvirtide. Nat. Rev. Drug Discov. 2 (2003) 345-346
27. Hruby V.J., et al. α-Melanotropin: the minimal active sequence in the frog skin bioassay. J. Med. Chem. 30 (1987) 2126-2130
28. Nargund R.P., et al. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J. Med. Chem. 49 (2006) 4035-4043
29. Rosen R.C., et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int. J. Impot. Res. 16 (2004) 135-142
30. Ruel R., et al. Beta-alanine dipeptides as MC4R agonists. Bioorg. Med. Chem. Lett. 13 (2003) 4341-4344
31. Zartler E.R., and Shapiro M.J. Fragonomics: fragment-based drug discovery. Curr. Opin. Chem. Biol. 9 (2005) 366-370
32. Erlanson D.A., McDowell R.S., and O'Brien T. Fragment-based drug discovery. J. Med. Chem. 47 (2004) 3463-3482
33. Evans B.E., et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31 (1988) 2235-2246
34. Schnur D.M., et al. Are target-family privileged substructures truly privileged?. J. Med. Chem. 49 (2006) 2000-2009
35. Bleicher K.H. Chemogenomics: Bridging a drug discovery gap. Curr. Med. Chem. 9 (2002) 2077-2084
36. Jacobson M., and Sali A. Comparative protein structure modeling and its applications to drug discovery. Annu. Rep. Med. Chem. 39 (2004) 259-276
37. Fabian M.A., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
38. Lipinski, C.A. and Hoffer, E. (2003) Compound properties and drug quality. Practice of Medicinal Chemistry (2nd edn), 341-349.
39. Gillespie P., and Goodnow Jr. R.A. The hit-to-lead process in drug discovery. Ann. Rep. Med. Chem. 39 (2004) 293-304
40. Baxter A., et al. Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. Bioorg. Med. Chem. Lett. 14 (2004) 2817-2822
41. Morwick T., et al. Evolution of the thienopyridine class of inhibitors of IκB kinase: Part I: hit-to-lead strategies. J. Med. Chem. 49 (2006) 2898-2908
42. McGovern S.L., et al. A common mechanism underlying promiscuous inhibitors from virtual and high throughput screening. J. Med. Chem. 45 (2002) 1712-1722
43. Stockman B.J., and Dalvit C. NMR screening techniques in drug discovery and drug design. Progr. Nucl. Magn. Reson. Spectrosc. 41 (2002) 187-231
44. Edwards B.S., et al. Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol. Pharmacol. 68 (2005) 1301-1310
45. Bologa C.G., et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2 (2006) 207-212
46. Haskell-Luevano C., et al. Truncation studies of α-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity. Peptides 17 (1996) 995-1002